Artemis One Health

GRANT-DRIVEN Projects, FLUCOP

Overview ALL ZOONOTIC projects:

Flunivac | Compare |  Zapi |  Flucop 

FLUCOP

 

Despite the development and licensure of influenza vaccines along with clinical evidence of their ability to protect against influenza, the potential correlates of protection induced by these vaccines are still not fully elucidated (http://www.flucop.eu). The availability of a tool-box of standardised, validated serological assays for human influenza vaccines, agreed and used by key parties in the private and in the public sector will have tremendous impact on the R&D process globally, and will pave the way for future investigation and definition of correlates of protection for these vaccines.

The ultimate goals will be achieved through three intermediate objectives:

  1. Achieving standardisation of haemagglutination inhibition and virus neutralisation assays.
  2. Advancing the understanding and application of cell-mediated immunity and neuraminidase assays as tools for evaluating influenza vaccine performance.
  3. Consideration of new technologies that could to be applied to investigate correlates of protection and population based evaluations of influenza vaccine.

Artemis One Health is involved in the development of novel analytical approaches to population-based evaluation of influenza vaccine effectiveness, in particular in the elderly.

 

Status: Ongoing…

FUNDING SOURCE

The FLUCOP project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115672, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. The total budget is of €13,999,164 with equal contribution from the IMI and European Federation of Pharmaceutical Industries and Associations (EFPIA).

PARTNERS

______________

The FLUCOP consortium is made up of 22 partners from eight European countries consisting of: 

  • Academic centres (both clinical and experimental),
  • Large industries (Sanofi- Pasteur, Novartis, GSK, Abbott, Crucell and AstraZeneca), Small-and medium-sized enterprises (SMEs),
  • Centres from national and/or supranational public health bodies, non-profit organisations and regulatory authorities
  • University of Surrey (SURREY) United Kingdom
  • The FLUCOP project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU), with funding from the EU FP7 Programme  

 

Quick view ALL "ONGOING" projects:

Compare | Chikungunya | Yellow fever | Zika | Elepant Herpes virus |  Rabies | Influenza |  Dengue EcoAlert Zapi |  Flucop | Flunivac | TBEV-COMEIN

 

 

 

 

Font resize
Contrast
X